MALIGNANT MESOTHELIOMA - THE ANTIPROLIFERATIVE EFFECT OF CYTOKINE COMBINATIONS ON 3 HUMAN MESOTHELIOMA CELL-LINES

被引:19
作者
HAND, AM
HUSGAFVELPURSIAINEN, K
TAMMILEHTO, L
MATTSON, K
LINNAINMAA, K
机构
[1] INST OCCUPAT HLTH,DEPT IND HYG & TOXICOL,MUTAGEN LAB,TOPELIUKSENKATU 41AA,SF-00250 HELSINKI,FINLAND
[2] UNIV HELSINKI,CENT HOSP,DEPT PULM MED,SF-00290 HELSINKI 29,FINLAND
关键词
RTNF; RIFN-ALPHA; RIFN-GAMMA; MESOTHELIOMA; INVITRO;
D O I
10.1016/0304-3835(91)90102-N
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumour necrosis factor (TNF) combined with gamma-interferon (IFN-gamma) is known to have antiproliferative effects on many tumour cells, both in vitro and in vivo. We investigated whether human mesothelioma cells would respond in a similar way. Mesothelioma cell lines established from primary tumours did not respond significantly in vitro to either TNF or IFN-gamma alone but were inhibited by combinations of TNF and IFN-gamma at concentrations as low as 5 ng/ml. In contrast, a mesothelioma cell line established from a metastatic tumour was sensitive to IFN-gamma both alone and in combination with TNF but not to TNF alone. We also looked at the responses of one primary tumour cell line and the metastatic tumour cell line to alpha-interferon (IFN-alpha) both alone and in combination with TNF. Both cells lines were sensitive to IFN-alpha but were more sensitive to the THF/IFN-alpha combination. We conclude that these low dose combinations of cytokines are worth further investigation in the development of mesothelioma therapy.
引用
收藏
页码:205 / 210
页数:6
相关论文
共 30 条
[21]   QUANTIFICATION AND CHARACTERIZATION OF HIGH-AFFINITY MEMBRANE-RECEPTORS FOR TUMOR-NECROSIS-FACTOR ON HUMAN-LEUKEMIC CELL-LINES [J].
SCHEURICH, P ;
UCER, U ;
KRONKE, M ;
PFIZENMAIER, K .
INTERNATIONAL JOURNAL OF CANCER, 1986, 38 (01) :127-133
[22]  
SCHILLER JH, 1987, CANCER RES, V47, P2809
[23]   TUMOR-NECROSIS-FACTOR - A CYTOKINE WITH MULTIPLE BIOLOGICAL-ACTIVITIES [J].
SEMENZATO, G .
BRITISH JOURNAL OF CANCER, 1990, 61 (03) :354-361
[24]   RECOMBINANT HUMAN-TUMOR NECROSIS FACTOR ADMINISTERED AS A 5-DAY CONTINUOUS INFUSION IN CANCER-PATIENTS - PHASE-I TOXICITY AND EFFECTS ON LIPID-METABOLISM [J].
SHERMAN, ML ;
SPRIGGS, DR ;
ARTHUR, KA ;
IMAMURA, K ;
FREI, E ;
KUFE, DW .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (02) :344-350
[25]   CLINICAL EFFECTS OF INTERFERON THERAPY WITH SPECIAL EMPHASIS ON ANTITUMOR EFFICACY [J].
STRANDER, HA .
ACTA ONCOLOGICA, 1989, 28 (03) :355-362
[26]   RECOMBINANT HUMAN-TUMOR NECROSIS FACTOR-ALPHA - EFFECTS ON PROLIFERATION OF NORMAL AND TRANSFORMED-CELLS INVITRO [J].
SUGARMAN, BJ ;
AGGARWAL, BB ;
HASS, PE ;
FIGARI, IS ;
PALLADINO, MA ;
SHEPARD, HM .
SCIENCE, 1985, 230 (4728) :943-945
[27]  
TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441
[28]   PHASE-I TRIAL OF RECOMBINANT INTERFERON-GAMMA IN CANCER-PATIENTS [J].
VADHANRAJ, S ;
ALKATIB, A ;
BHALLA, R ;
PELUS, L ;
NATHAN, CF ;
SHERWIN, SA ;
OETTGEN, HF ;
KROWN, SE .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (02) :137-146
[29]  
WAGNER J C, 1960, Br J Ind Med, V17, P260
[30]   HUMAN-TUMOR NECROSIS FACTOR PRODUCED BY HUMAN B-CELL LINES - SYNERGISTIC CYTO-TOXIC INTERACTION WITH HUMAN INTERFERON [J].
WILLIAMSON, BD ;
CARSWELL, EA ;
RUBIN, BY ;
PRENDERGAST, JS ;
OLD, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (17) :5397-5401